A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy AdultsAndrás Nagy, Zhaoyang Li, Fred Okonneh et al.|Journal of Clinical Immunology|2023Cited by 3
Facilitated subcutaneous immunoglobulin 10% at a target dose of 0.4 g/kg/infusion is well tolerated with accelerated or no dose ramp-up in healthy participantsZhaoyang Li, Leman Yel, András Nagy et al.|Clinical Immunology|2023Cited by 1
Feasibility Assessment of Facilitated Subcutaneous Immunoglobulin 1.0 G/Kg with Abbreviated Dose Ramp-Up and without Ramp-Up: A Phase 1 Tolerability and Safety Study in Healthy Adults (P6-4.003)Zhaoyang Li, Leman Yel, Hakan Ay et al.|Neurology|2023Cited by 0
Tolerability and safety of facilitated subcutaneous immunoglobulin 20% in healthy adults: a phase 1 open-label studyAndrás Nagy, Zhaoyang Li, Noor M. Khaskhely et al.|Clinical Immunology|2023Cited by 0